Drug Interactions Clinical Trial
Official title:
A Single-Centre, Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Interaction Between Vicodin® CR and Ethanol in Healthy Male and Female Moderate Alcohol Drinkers
NCT number | NCT00429468 |
Other study ID # | M06-835 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | January 29, 2007 |
Last updated | October 24, 2007 |
Start date | January 2007 |
Verified date | October 2007 |
Source | Abbott |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this research study is to determine if varying strengths of ethanol affect the drug level and safety profile of Vicodin® CR.
Status | Completed |
Enrollment | 25 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 19 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Males and females ages 19 to 55 - If female, must be of non-child bearing potential or practicing birth control - Current alcohol users who are classified as moderate drinkers (defined as 7-21 drinks per week) Exclusion Criteria: - Intolerance towards ethanol - Is allergic to or has a serious reaction to hydrocodone, other opioids, or acetaminophen - Significant GI narrowing or abnormality with a potential to inhibit GI motility or tablet transport - History of seizures or convulsions, head injury or other intracranial lesions, or a pre-existing increase in intracranial pressure - Has any clinically significant abnormalities on physical examination, ECG, or laboratory values - Treatment with any investigational drug within 30 days of administration of study drug in the Treatment Phase |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Abbott |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Standard pharmacokinetic assessments | |||
Primary | statistical, clinical and laboratory procedures |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT01925638 -
Effect of Ketoconazole on the Pharmacokinetics of Refametinib
|
Phase 1 | |
Completed |
NCT00621699 -
Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00442585 -
S(+)-Ibuprofen Effects on Asprin Treated Volunteers
|
Phase 1 | |
Completed |
NCT00200759 -
Drug Interactions and Bioavailability of Cranberry
|
Phase 1 | |
Active, not recruiting |
NCT06401863 -
Shared Decision for Drug Interactions in Oral Anticoagulation
|
N/A | |
Completed |
NCT00915746 -
A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03748745 -
A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03324685 -
A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen
|
Phase 1 | |
Completed |
NCT05433896 -
Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions
|
Phase 1 | |
Recruiting |
NCT03307863 -
Effect of Anti-epileptic Drugs on Etonogestrel-releasing Implant Pharmacokinetics in Women With Epilepsy
|
Phase 4 | |
Completed |
NCT02706535 -
A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential
|
Phase 1 | |
Completed |
NCT02097953 -
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
|
Phase 0 | |
Completed |
NCT02147808 -
A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01364987 -
Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00709982 -
A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM) /Ethinyl Estradiol (EE) in Healthy Women.
|
Phase 1 | |
Completed |
NCT00810303 -
Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CYP3A4, UGT1A1, ABCB1 and ABCC2
|
Phase 1 | |
Completed |
NCT04252300 -
Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants
|
Phase 1 | |
Completed |
NCT02576366 -
Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus
|
Phase 4 | |
Completed |
NCT02159326 -
Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women
|
Phase 1 |